Scott Reed, MD
Family Medicine · Pinehurst, IDNPI 1326090754
Payments from drug & device makers
Across 219 payments — averaging $14.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$561
- Amgen$516
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$368
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$329
- AstraZeneca$249
- Otsuka America Pharmaceutical, Inc.$208
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,21398%
- Education$512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $561 |
| Amgen(2 entities) | 32 | $516 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $368 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $329 |
| AstraZeneca | 17 | $249 |
| Otsuka America Pharmaceutical, Inc. | 11 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $150 |
| Novo Nordisk | 10 | $148 |
| Pfizer | 6 | $126 |
| Lilly USA, LLC | 7 | $88 |
| Bayer | 5 | $87 |
| Sumitomo Pharma America, Inc. | 4 | $77 |
| Biohaven Pharmaceuticals, Inc. | 3 | $57 |
| GSK | 3 | $53 |
| Eisai Inc. | 3 | $49 |
| Alkermes, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Vertex | 1 | $22 |
| Abbott | 1 | $21 |
| Novartis | 1 | $14 |
How this compares
$3,264 in reported general payments places this provider in the 90th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 103 | $71,392 |
| OzempicSemaglutide | 67 | $67,872 |
| RexultiBrexpiprazole | 39 | $57,826 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $44,662 |
| OxycontinOxycodone Hcl | 13 | $29,712 |
| CaplytaLumateperone Tosylate | 26 | $20,921 |
| MyrbetriqMirabegron | 51 | $19,785 |
| XareltoRivaroxaban | 18 | $16,823 |
| TrintellixVortioxetine Hydrobromide | 29 | $10,682 |
| Pregabalin | 137 | $7,780 |
| FarxigaDapagliflozin Propanediol | 11 | $6,271 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 294 | $6,231 |
| Hysingla ErHydrocodone Bitartrate | 12 | $6,230 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,004 |
| Fentanyl | 51 | $4,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $71,392103 claims |
| Novo NordiskOzempic | $148 | $67,87267 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $208 | $57,82639 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $53 | $49,66670 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $368 | $20,92126 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $19,78551 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $150 | $10,68229 claims |
| AstraZenecaFarxiga | $249 | $6,27111 claims |
| Eisai Inc.Dayvigo | $49 | $3,84213 claims |
| Lilly USA, LLCOlanzapine | $88 | $1,24639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 803 family medicine providers in Idaho.
Other family medicine in Pinehurst
- Mark TurnerMeridian$40.5M
- David ButukMeridian$15.2M
- Gary SoucieBlackfoot$5.8M
- Brock McConneheyBoise$4.5M
- William LaitinenMiddleton$1.1M
- Diane McConneheyBoise$681K
- Flint PackerIdaho Falls$587K
- Paul BeckettBlackfoot$344K
- Elaine DavidsonMeridian$303K
- Kenneth CongerSandpoint$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.